Completed PHASE2 INTERVENTIONAL NCT00136461

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

A Randomized Phase II Trial of All-Trans Retinoic Acid and One of Two Schedules of Bryostatin 1 in Patients With Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Sponsor: Brigham and Women's Hospital

Conditions Acute Myelogenous Leukemia Myelodysplastic Syndrome

Interventions All-trans retinoic acid Bryostatin 1

Updated 5 times since 2017 Last updated: Mar 9, 2011 Started: May 31, 1997 Primary completion: Aug 31, 2000 Completion: Aug 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myelogenous Leukemia and Myelodysplastic Syndrome and is currently completed. Brigham and Women's Hospital leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital
Dana-Farber Cancer Institute

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States